Condition: Laryngeal Cancer · Hypopharyngeal Cancer · Sponsor: Insel Gruppe AG, University Hospital Bern
The investigators will obtain three-monthly voice recordings and fiberendoscopic examinations of the larynx/hypopharynx for a minimal period of 6 months from all laryngeal/hypopharyngeal squamous cell carcinoma (LSCC/HPSCC) patients, who have successfully completed curative primary treatment, except those who underwent total laryngectomy. Furthermore, the investigators will ask the patients to fill out the voice handicap index-30 questionnaire (VHI-30) during each study visit. The VHI-30 allows to make a subjective assessment of the patients' own vocal problem. The primary objective is to assess the feasibility and compliance of longterm regular voice monitoring in LSCC and HPSCC follow-up.
This description comes directly from the study's public registry record.
Roland Giger, Prof. · +41 31 632 29 31 · roland.giger@insel.ch
Miranda Visini, Dr. med. · +41 31 632 88 59 · miranda.visini@insel.ch
Always discuss trial participation with your own doctor first.
| Department of Oto-Rhino-Laryngology, Head and Neck Surgery, Inselspital, Bern University Hospital | Bern, Switzerland | Recruiting |
| Department of Oto-Rhino-Larnygology, Head and Neck Surgery, University Hospital Zurich | Zurich, Switzerland | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05894070